AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nord, C. E.
Right arrow Articles by Wahlund, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nord, C. E.
Right arrow Articles by Wahlund, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2006, p. 3375-3380, Vol. 50, No. 10
0066-4804/06/$08.00+0     doi:10.1128/AAC.00373-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Effect of Tigecycline on Normal Oropharyngeal and Intestinal Microflora

Carl Erik Nord,* Eva Sillerström, and Elisabeth Wahlund

Division of Clinical Bacteriology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, SE-141 86 Stockholm, Sweden

Received 27 March 2006/ Returned for modification 15 May 2006/ Accepted 30 June 2006

Antibacterial agents disrupt the ecological balance of the normal human microflora. Tigecycline, a member of a new class of antibiotics (glycylcyclines), has been shown to have a potent broad-spectrum activity against most gram-positive and gram-negative aerobic and anaerobic bacteria. The aim of the study was to investigate the ecological effects of tigecycline on the normal oropharyngeal and intestinal microflora of healthy subjects. Thirteen healthy white subjects (six females and seven males) between 20 and 31 years of age received 100 mg of tigecycline in the morning on day 1 as a 30-min intravenous infusion followed by a 50-mg dose of tigecycline every 12 h as a 30-minute infusion for 10 days. One subject was withdrawn on day 2 because of an adverse event (urticaria). Serum, saliva, and fecal samples were collected before, during, and after administration for microbiological cultivation and for assays of tigecycline. All new colonizing bacteria were tested for susceptibility (resistance of ≥8 mg/liter) during the investigation period. The fecal concentrations on day 8 were from 3.0 to 14.1 mg/kg, with a mean value of 6.0 mg/kg and a median value of 5.6 mg/kg. The saliva concentrations were generally low (0 to 0.12 mg/liter). A minor effect on the oropharyngeal microflora was observed. The numbers of enterococci and Escherichia coli cells in the intestinal microflora were reduced at day 8 (P < 0.05), while those of other enterobacteria and yeasts increased. There was a marked reduction of lactobacilli and bifidobacteria (P < 0.05) but no impact on bacteroides. No Clostridium difficile strains were isolated. Two Klebsiella pneumoniae strains and five Enterobacter cloacae strains resistant to tigecycline were found on day 8.


* Corresponding author. Mailing address: Division of Clinical Bacteriology, F82, Department of Laboratory Medicine, Karolinska University Hospital Huddinge, SE-141 86 Stockholm, Sweden. Phone: 46-8-585 878 38. Fax: 46-8-711 39 18. E-mail: carl.erik.nord{at}ki.se.


Antimicrobial Agents and Chemotherapy, October 2006, p. 3375-3380, Vol. 50, No. 10
0066-4804/06/$08.00+0     doi:10.1128/AAC.00373-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2006 by the American Society for Microbiology. All rights reserved.